参麦注射液对中晚期非小细胞肺癌患者近期生存质量影响  

Effect of Shenmai injection on short-term quality of life in patients with advanced nonsmall cell lung cancer

作　　者：徐晓翌 吴锡林 钟津津 许远 张炼 王磊 XU Xiaoyi;WU Xilin;ZHONG Jinjin;XU Yuan;ZHANG Lian;WANG Lei

机构地区：[1]衢州市中医医院,浙江衢州324000 [2]衢州市人民医院,浙江衢州324000

出　　处：《中医临床研究》2024年第36期62-67,共6页Clinical Journal Of Chinese Medicine

基　　金：浙江省医学会临床科研基金项目(2020ZYC-A87)。

摘　　要：目的:对参麦注射液在治疗中晚期非小细胞肺癌化疗患者中的效果进行生存质量的近期评估。方法:将60例中晚期非小细胞肺癌患者随机分成两组进行研究。治疗组30例采用化疗±免疫检查点抑制剂配合参麦注射液治疗,对照组30例采用单纯化疗±免疫检查点抑制剂治疗,21 d为一个疗程,连续治疗两个疗程,采用欧洲癌症研究和治疗组织肿瘤肺癌患者生存质量量表(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 43,EORTC QLQLC43)进行生存质量评估。结果:经过治疗,治疗组在核心量表的所有功能领域及整体健康状况的评分均显示出上升趋势,表明患者的功能状态和生命质量得到了显著改善。特别是在情绪功能和整体健康状况方面,与治疗前的评分相比,差异有统计学意义(P<0.05);在症状子量表的评估中,除了恶心呕吐和经济困难2项指标外,其他所有指标的评分均较治疗前有所下降,提示患者的症状得到了缓解,特别是在疼痛和失眠症状上,差异具有统计学意义(P<0.05)。对照组在治疗后,症状子量表中的疲倦、恶心呕吐、食欲丧失和便秘等症状的评分与治疗前相比差异有统计学意义(P<0.05),提示这些症状有所加重。在两组治疗后的对比中,除社会功能、腹泻和经济困难3项指标外,治疗组在其他所有指标上的评分与对照组相比,差异均有统计学意义(P<0.05),表明治疗组的治疗效果在多个方面优于对照组。经过治疗,对比两组在肺癌模块各项目上的评分,结果显示在气促、咳嗽、咯血、口腔疼痛、吞咽困难及手足、手或肩部和其他部位的疼痛方面,两组间差异有统计学意义(P<0.05),表明治疗对这些症状的影响在不同组间有显著不同。结论:参麦注射液具有减轻中晚期非小细胞肺癌化疗±免疫检查点抑制剂患者相关临床症状和治疗相关症状,以及改善患者生Objective:To evaluate the effect of Shenmai injection(参麦注射液)on short-term quality of life(QOL)in patients with advanced non-small cell lung cancer(NSCLC)undergoing chemotherapy by using the EORTC QLQ-LC43 scale,the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.Methods:Sixty patients with advanced non-small cell lung cancer were randomly divided into two groups for the study.In the treatment group,30 cases were treated with chemotherapy±immune checkpoint inhibitor combined with Shenmai injection;In the control group,30 patients were treated with single chemotherapy±immune checkpoint inhibitor for 21 days,which was one course of treatment,and the quality of life was assessed by using EORTC QLQ-LC43 scale.Results:After treatment,the treatment group showed an upward trend in all functional areas of the core scale,as well as in overall health status,indicating that patients’functional status and quality of life were significantly improved.In particular,there were significant differences in emotional function and overall health status compared with pre-treatment scores(P<0.05).In the symptom subscale assessment,the scores of all indicators except nausea and vomiting and financial hardship decreased compared with those before treatment,indicating that the symptoms of the patients had been relieved and the differences in pain and insomnia symptoms were statistically significant(P<0.05).In contrast,the scores of fatigue,nausea and vomiting,loss of appetite and constipation in the symptom subscale of the control group were significantly different after treatment compared with those before treatment(P<0.05),indicating that these symptoms were aggravated.In the comparison between the two groups after treatment,except for the three indexes of social function,diarrhea and economic hardship,the scores of the treatment group were statistically significant compared with those of the control group(P<0.05),indicating that the treatment effect of the treatment group was better

关 键 词：参麦注射液 中晚期非小细胞肺癌 欧洲癌症研究与治疗组织生命质量测定量表 生存质量 

分 类 号：R734.2[医药卫生—肿瘤]